2010
DOI: 10.1021/nn1024303
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Graphene has emerged as interesting nanomaterials with promising applications in a range of fields including biomedicine. In this work, for the first time we study the long-term in vivo biodistribution of (125)I-labeled nanographene sheets (NGS) functionalized with polyethylene glycol (PEG) and systematically examine the potential toxicity of graphene over time. Our results show that PEGylated NGS mainly accumulate in the reticuloendothelial system (RES) including liver and spleen after intravenous administrat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

16
619
1
2

Year Published

2013
2013
2017
2017

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 770 publications
(638 citation statements)
references
References 34 publications
16
619
1
2
Order By: Relevance
“…After 9 d, little orange region can be still observed in the liver, suggesting that GO/AgNPs can be excreted completely from the liver. This result can be supported from the reference published by Yang et al PEGylated GO mainly accumulates in the liver and spleen after intravenous administration and would www.advancedsciencenews.com www.advhealthmat.de be gradually cleared for 90 d. [45] Therefore, under the prerequisite of safety in vivo, GO/AgNPs can be used as a long-term contrast agent of enhanced-CT for diagnosis and treatment of pulmonary disease in the presence of simvastatin. The effects of different injection dose on CT imaging of GO/AgNPs were shown in Figure 5B after 24 h postintravenous coadministration with simvastatin (20 mg per kg bw).…”
Section: Ct Imaging Of Go/agnps In Vivomentioning
confidence: 65%
See 3 more Smart Citations
“…After 9 d, little orange region can be still observed in the liver, suggesting that GO/AgNPs can be excreted completely from the liver. This result can be supported from the reference published by Yang et al PEGylated GO mainly accumulates in the liver and spleen after intravenous administration and would www.advancedsciencenews.com www.advhealthmat.de be gradually cleared for 90 d. [45] Therefore, under the prerequisite of safety in vivo, GO/AgNPs can be used as a long-term contrast agent of enhanced-CT for diagnosis and treatment of pulmonary disease in the presence of simvastatin. The effects of different injection dose on CT imaging of GO/AgNPs were shown in Figure 5B after 24 h postintravenous coadministration with simvastatin (20 mg per kg bw).…”
Section: Ct Imaging Of Go/agnps In Vivomentioning
confidence: 65%
“…Therefore, the diagnosis of GO/AgNPs to renal dysfunction would have important clinical and research significance. Previously, many works [33,34,37,[51][52][53] have been reported that GO can be gradually cleared by both renal excretion, meaning that GO/AgNPs have great potential in diagnosis and treatment of the nephropathy. As can be seen from Figure 6A, after intravenous administration with 0.5-10 mg per kg bw of GO/AgNPs for 36 h, the highquality renal imaging can be clearly observed by enhanced-CT under the protection of 20 mg per kg bw simvastatin.…”
Section: Ct Imaging Of Go/agnps In Vivomentioning
confidence: 99%
See 2 more Smart Citations
“…Radio-graphene has been designed in various synthetic methods [22][23][24][25][26][27]. Functional moiety exposed at the edge of graphene oxide (GO) can be modified for radionuclide labeling.…”
mentioning
confidence: 99%